Ovarian cancer and genetic susceptibility: Association of A61G polymorphism in the EGF gene

Experimental Biology and Medicine

Volumn 234, Issue 3, 2009, Pages 241-245

  Araújo, Ana Paula ^a,b   Ribeiro, Ricardo ^a,c   Pereira, Deolinda ^a   Pinto, Daniela ^a   Sousa, Berta ^a   Catarino, Raquel ^a   Medeiros, Rui ^a,c  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF AVEIRO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Egf polymorphism; EGFR; Ovarian cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA DETERMINATION; DNA POLYMORPHISM; EPIDERMAL GROWTH FACTOR GENE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PORTUGAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; OVARY TUMOR; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; EPIDERMAL GROWTH FACTOR; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 63349107870     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0805-RM-146     Document Type: Article

References (37)

1. Henson ES, Gibson SB. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal 18:2089-2097, 2006.
2. Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De Luca A, Caponigro F, Salomon DS. The ErbB receptors and their ligands in cancer:an overview. Curr Drug Targets 6:243-257, 2005.
3. Araújo A, Ribeiro R, Azevedo I, Coelho A, Soares M, Sousa B, Pinto D, Lopes C, Medeiros R, Scagliotti GV. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist 12:201-210, 2007.
4. Ciardiello F, Tortora G. Interactions between the epidermal growth factor receptor and type I protein kinase A:biological significance and therapeutic implications. Clin Cancer Res 4:821-828, 1998.
5. Levitzki A. EGF receptor as a therapeutic target. Lung Cancer 41: S9-S14, 2003.
6. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005.
7. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995.
8. Maruo T, Ladines-Llave CA, Samoto T, Matsuo H, Manalo AS, Ito H, Mochizuki M. Expression of epidermal growth factor and its receptor in the human ovary during follicular growth and regression. Endocrinology 132:924-931, 1993.
9. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, Hutchinson PE, Osborne JE, Lear JT, Smith AG, Hutchinson IV. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359:397-401, 2002.
10. Medeiros R, Pereira D, Afonso N, Palmeira C, Faleiro C, Afonso-Lopes C, Freitas-Silva M, Vasconcelos A, Costa S, Osório T, Lopes C. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma:glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8:156-161, 2003.
11. Santos AM, Sousa H, Pinto D, Portela C, Pereira D, Catarino R, Duarte I, Lopes C, Medeiros R. Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer. Eur J Cancer 42:958-963, 2006.
12. Müllenbach R, Lagoda PJ, Welter C. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet 5:391, 1989.
13. Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet 33:238-244, 2003.
14. Ponder BA. Cancer genetics. Nature 411:336-341, 2001.
15. Peto J. Cancer epidemiology in the last century and the next decade. Nature 411:390-395, 2001.
16. Rees J. Functional polymorphism in EGF gene and malignant melanoma. Lancet 360:570, 2002.
17. McCarron SL, Bateman AC, Theaker JM, Howell WM. EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma. Int J Cancer 107:673-675, 2003.
18. Amend KL, Elder JT, Tomsho LP, Bonner JD, Johnson TM, Schwartz J, Berwick M, Gruber SB. EGF gene polymorphism and the risk of incident primary melanoma. Cancer Res 64:2668-2672, 2004.
19. Bhowmick DA, Zhuang Z, Wait SD, Weil RJ. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 64:1220-1223, 2004.
20. Goto Y, Ando T, Goto H, Hamajima N. No association between EGF gene polymorphism and gastric cancer. Cancer Epidemiol Biomarkers Prev 14:2454-2456, 2005.
21. Costa BM, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, Pardal F, Suriano G, Machado JC, Lopes JM, Reis RM. Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res 13:2621-2626, 2007.
22. Ribeiro R, Soares A, Pinto D, Catarino R, Lopes C, Medeiros R. EGF genetic polymorphism is associated with clinical features but not malignant phenotype in neurofibromatosis type 1 patients. J Neurooncol 81:225-229, 2007.
23. Wells A. EGF receptor. Int J Biochem Cell Biol 31:637-643, 1999.
24. Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal 17:1183-1193, 2005.
25. Salazar G, Gonzalez A. Novel mechanism for regulation of epidermal growth factor receptor endocytosis revealed by protein kinase A inhibition. Mol Biol Cell 13:1677-1693, 2002.
26. Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs:implications for cancer immunotherapy. Proc Natl Acad Sci U S A 102:1915-1920, 2005.
27. Zhao X, Dai W, Zhu H, Zhang Y, Cao L, Ye Q, Lei P, Shen G. Epidermal growth factor (EGF) induces apoptosis in a transfected cell line expressing EGF receptor on its membrane. Cell Biol Int 30:653-658, 2006.
28. Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN, Butzow R. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med 84:671-681, 2006.
29. Ozcakir HT, Giray SG, Ozbilgin MK, Uyar Y, Lacin S, Caglar H. Immunohistochemical detection of transforming growth factor-alpha, epidermal growth factor, and vascular endothelial growth factor expression in hyperstimulated rat ovary. Acta Obstet Gynecol Scand 84:887-893, 2005.
30. Leung PCK, Steele GL. Intracellular signaling in the gonads. Endocr Rev 13:476-498, 1992.
31. Marui T, Ladines-Llave CA, Samoto T, Matsuo H, Manalo AS, Ito H, Mochizuki M. Expression of epidermal growth factor and its receptor in the human ovary during follicular growth and regression. Endocrinology 132:924-931, 1993.
32. Ashkenazi H, Cao X, Motola S, Popliker M, Conti M, Tsafriri A. Epidermal growth factor family members:endogenous mediators of the ovulatory response. Endocrinology 146:77-84, 2005.
33. Conti M, Hsieh M, Park J-Y, Su Y-Q. Role of the epidermal growth factor network in ovarian follicles. Mol Endocrinol 20:715-723, 2006.
34. Hsueh AJ, Welsh TH, Jones PB. Inhibition of ovarian and testicular steroidogenesis by epidermal growth factor. Endocrinology 108:2002-2004, 1981.
35. Jones PBC, Welsh TH, Hsueh AJW. Regulation of ovarian progestin production by epidermal growth factor in cultured rat granulosa cells. J Biol Chem 257:11268-11273, 1982.
36. Pulley DD, Marrone BL. Inhibitory action of epidermal growth factor on progesterone biosynthesis in hen granulosa cells during short term culture:two sites of action. Endocrinology 118:2284-2291, 1986.
37. Findlay JK, Drummond AE. Regulation of the FSH receptor in the ovary. Trends Endocrinol Metab 10:183-188, 1999.